On October 27, a program signing ceremony between Changzhou and Ypsomed took place in the city hall. Deputy Mayor Huan Heng met with the executives of Ypsomed via video and witnessed the signing ceremony. Also present was Sacha Bachmann, consul general of Switzerland in Shanghai.

As a strong manufacturing base, Changzhou boasts a variety of industrial categories and a complete ecosystem for industry. Acting upon the guidelines of the 20th CPC National Congress, the government will further promote the "532" Development Strategy to build an international star city of manufacturing. The signing opens a new chapter for Ypsomed to expand its business in China, and the Changzhou government will follow up on the program to give its full support.

Headquartered in Burgdorf, Switzerland, Ypsomed is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years� experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies including AstraZeneca, Bristol Myers Squibb, Pfizer, Genetech, etc.

In 2021, the company’s global sales revenue reached 465 million CHF (approximately 3.17 billion RMB).

The medical apparatus program signed this time will be established at the life science park in the CND, Changzhou. It marks Ypsomed’s first manufacturing base in China. The program, with a total investment of over 40 million euros, will focus on the R&D, production and assembly of injection pens and needles. A smart plant, meeting the standards of Industry 4.0, will be established, and is expected to go into production in 2024.